Sunshine Biopharma, Inc.
SBFM
$1.05
$0.021.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -8.92% | 0.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.92% | 0.07% | |||
| Cost of Revenue | -12.54% | 5.95% | |||
| Gross Profit | -1.45% | -10.21% | |||
| SG&A Expenses | 34.17% | -18.93% | |||
| Depreciation & Amortization | 3.24% | 32.14% | |||
| Other Operating Expenses | 5.50% | 6.39% | |||
| Total Operating Expenses | 2.88% | -4.36% | |||
| Operating Income | -211.69% | 46.41% | |||
| Income Before Tax | -69.65% | 48.42% | |||
| Income Tax Expenses | 397.23% | 34.32% | |||
| Earnings from Continuing Operations | -142.24% | 50.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -142.24% | 50.09% | |||
| EBIT | -211.69% | 46.41% | |||
| EBITDA | -257.87% | 52.65% | |||
| EPS Basic | -127.42% | 50.75% | |||
| Normalized Basic EPS | -229.39% | 50.94% | |||
| EPS Diluted | -127.42% | 50.75% | |||
| Normalized Diluted EPS | -229.39% | 50.94% | |||
| Average Basic Shares Outstanding | 6.51% | 1.33% | |||
| Average Diluted Shares Outstanding | 6.51% | 1.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||